These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2199292)

  • 21. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.
    DuPont HL; Flores Sanchez J; Ericsson CD; Mendiola Gomez J; DuPont MW; Cruz Luna A; Mathewson JJ
    Am J Med; 1990 Jun; 88(6A):15S-19S. PubMed ID: 2192553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
    Graham DY; Hepps KS; Ramirez FC; Lew GM; Saeed ZA
    Scand J Gastroenterol; 1993 Nov; 28(11):939-42. PubMed ID: 8284627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.
    Graham DY; Estes MK; Gentry LO
    Gastroenterology; 1983 Nov; 85(5):1017-22. PubMed ID: 6352386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.
    Johnson PC; Ericsson CD; DuPont HL; Morgan DR; Bitsura JA; Wood LV
    JAMA; 1986 Feb; 255(6):757-60. PubMed ID: 3944976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
    Berstad A; Olafsson S; Tefera S; Berstad K; Hundal O; Bergseth M; Wilhelmsen I
    J Physiol Pharmacol; 1996 Mar; 47(1):31-49. PubMed ID: 8777305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Campylobacter pylori and therapy with bismuth salts].
    Börsch G
    Med Monatsschr Pharm; 1988 Sep; 11(9):301-7. PubMed ID: 3067064
    [No Abstract]   [Full Text] [Related]  

  • 29. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety profile of De-Nol.
    Bader JP
    Digestion; 1987; 37 Suppl 2():53-9. PubMed ID: 3622947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
    Wagner S; Gebel M; Haruma K; Bär W; Lange P; Freise J; Gladziwa U; Schmidt FW
    Gut; 1992 Feb; 33(2):179-83. PubMed ID: 1347278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
    Fedotin MS
    Postgrad Med; 1993 Sep; 94(3):38-40, 43-5. PubMed ID: 8361941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
    Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of Helicobacter pylori infection: current status].
    Wagner S; Gebel M; Manns M
    Z Gastroenterol; 1993; 31(7-8):459-63. PubMed ID: 8379235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of traveler's diarrhea.
    Tellier R; Keystone JS
    Infect Dis Clin North Am; 1992 Jun; 6(2):333-54. PubMed ID: 1624780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
    Wilhelmsen I; Weberg R; Berstad K; Hausken T; Hundal O; Berstad A
    Hepatogastroenterology; 1994 Feb; 41(1):43-7. PubMed ID: 8175114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole.
    Nijevitch AA; Farztdinov KM; Sataev VU; Khasanov RSh ; Katayev VA; Khusnutdinov SM; Akhunov ED; Kazykhanov NS
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1243-50. PubMed ID: 11129216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea.
    Ericsson CD
    Clin Infect Dis; 2005 Dec; 41 Suppl 8():S557-63. PubMed ID: 16267719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
    Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
    Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.